Multi-parameter MRI-based model for the prediction of early recurrence of hepatitis B-associated hepatocellular carcinoma after microwave ablation
Frontiers in Cellular and Infection Microbiology · 27.08.2025 · 15
DOI: 10.3389/fcimb.2025.1638779 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Cellular and Infection Microbiology, online erschienen am 27.08.2025. Verfasst von Ying Zhang und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hepatology, Qilu Hospital of Shandong University, Jinan, China. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, Hepatitis B, Microwaves. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Objectives
To establish and validate a multi-parameter model for the prediction of early recurrence in patients with hepatitis B-associated hepatocellular carcinoma (HBV-HCC) after microwave ablation.
Methods
This study retrospectively reviewed the clinical features and preoperative magnetic resonance imaging (MRI) scans of 166 patients with HBV-HCC who underwent microwave ablation at two hospitals. The training cohort comprised 116 patients from the first hospital (n = 116; mean age, 56 years; 84 male patients), while 50 patients from the second hospital constituted the external validation cohort (n = 50; mean age, 60 years; 38 male patients). A transformer-based deep learning network was used to fuse images from multi-sequence MRI and predict recurrence within 1 year after microwave ablation. Additionally, a nomogram based on deep learning radiomics and clinical features was developed and externally validated in a validation group from a second hospital.
Results
The combined model was better than the clinical model and MRI model in predicting early recurrence of hepatitis B-associated hepatocellular carcinoma within 1 year after microwave ablation. Nomograms based on joint models include aspartate aminotransferase, portal hypertension, and deep learning-based radiomics scores. The areas under curves of the models in the training group and the validation group were 0.868 (95% CI: 0.793–0.924) and 0.842 (95% CI: 0.711–0.930), respectively, indicating high prediction ability. The results of decision curve analysis showed that the combined model had good clinical application value and correction effect.
Conclusions
Our nomogram combined with clinical features and preoperative magnetic resonance imaging features effectively predicted early recurrence of hepatitis B-associated hepatocellular carcinoma within 1 year after microwave ablation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Hepatology, Qilu Hospital of Shandong University, Jinan, China.
- School of Radiology, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China.
- Department of Radiology, Qilu Hospital of Shandong University, Jinan, China.
Zitieren
APA
Zhang, Y., Yu, J. J., Chen, W., Liu, B., Wei, X. F., Wang, Z. H., Li, X., Gao, S., & Wang, K. (2025). Multi-parameter MRI-based model for the prediction of early recurrence of hepatitis B-associated hepatocellular carcinoma after microwave ablation. Frontiers in Cellular and Infection Microbiology, 15. https://doi.org/10.3389/fcimb.2025.1638779
Vancouver
Zhang Y, Yu JJ, Chen W, Liu B, Wei XF, Wang ZH, et al. Multi-parameter MRI-based model for the prediction of early recurrence of hepatitis B-associated hepatocellular carcinoma after microwave ablation. Frontiers in Cellular and Infection Microbiology. 2025;15. doi:10.3389/fcimb.2025.1638779
BibTeX
@article{Zhang2025,
author = {Zhang, Ying and Yu, Jing-Jing and Chen, Wei and Liu, Bo and Wei, Xue-Fei and Wang, Zhao-Hui and Li, Xue and Gao, Shuai and Wang, Kai},
title = {Multi-parameter MRI-based model for the prediction of early recurrence of hepatitis B-associated hepatocellular carcinoma after microwave ablation},
journal = {Frontiers in Cellular and Infection Microbiology},
year = {2025},
volume = {15},
doi = {10.3389/fcimb.2025.1638779}
}
EUVIMED